OCT 29, 2026 · JOURNAL ARTICLE
Probable Stevens–Johnson Syndrome During Taletrectinib Treatment After Crizotinib‐Related Rash in ROS1 ‐Positive Lung Cancer
Respirology Case Reports
ABSTRACT Severe cutaneous adverse reactions to taletrectinib, a next‐generation ROS1 inhibitor for ROS1‐rearranged non‐small cell lung cancer, remain poorly described. A 52‐year‐ol